ART-123 will be administered via intravenous drip.

Open label, non-controlled, dose-escalating, multicenter, Phase 1 study to assess the safety and tolerability of ART-123 in combination with FOLFOX and bevacizumab in metastatic colorectal cancer patients

A Phase 3 Study to Assess the Preventive Effect of ART-123 for Sensory Symptoms of Oxaliplatin-Induced Peripheral Neuropathy.